c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Blood

• Publication date

  2008-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2008-03-146704PMID 18796631
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.

  2008cited by this paper
• Proteasome Dependent Auto-Regulation of Bruton’s

  2008cited by this paper
• Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.

  2008cited by this paper
• The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.

  2008cited by this paper
• Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB.

  2008cited by this paper
• c-Abl Kinase Inhibitors Overcome CD40-Mediated Drug Resistance in CLL.

  2007cited by this paper
• The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

  2007cited by this paper
• Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection

  2007cited by this paper
• The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.

  2007cited by this paper
• Translational Repression of MCL-1 Couples Stress-induced eIF2α Phosphorylation to Mitochondrial Apoptosis Initiation*

  2007cited by this paper
• Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

  2007cited by this paper
• Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

  2007cited by this paper
• Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.

  2007cited by this paper
• Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity.

  2007cited by this paper
• MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.

  2007cited by this paper
• Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

  2007cited by this paper
• Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells

  2007cited by this paper
• Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

  2007cited by this paper
• CD154 induces a switch in pro‐survival Bcl‐2 family members in chronic lymphocytic leukaemia

  2007cited by this paper
• Significant Activity of Dasatinib in CLL Demonstrated by Ex-Vivo Assay.

  2007cited by this paper
• A Phase II Study of Dasatinib in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL/SLL).

  2007cited by this paper
• Dasatinib Induces Apoptosis in Chronic Lymphocytic Leukemia and Enhances the Activity of Rituximab and Fludarabine.

  2007cited by this paper
• Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

  2006cited by this paper
• The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

  2006cited by this paper
• Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1.

  2006cited by this paper
• c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications.

  2006cited by this paper
• CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.

  2006cited by this paper
• Regulatory phosphorylation of Bim: sorting out the ERK from the JNK

  2005cited by this paper
• In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

  2005cited by this paper
• Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.

  2005cited by this paper
• Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

  2005cited by this paper
• Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.

  2005cited by this paper
• Notch and NOXA-related pathways in melanoma cells.

  2005cited by this paper
• Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

  2005cited by this paper
• Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation

  2005cited by this paper
• Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation*

  2005cited by this paper
• An inhibitor of Bcl-2 family proteins induces regression of solid tumours

  2005cited by this paper
• High expression of Bfl‐1 contributes to the apoptosis resistant phenotype in B‐cell chronic lymphocytic leukemia

  2005cited by this paper
• CD40 stimulation of B‐cell chronic lymphocytic leukaemia cells enhances the anti‐apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T‐lymphocyte attack

  2004cited by this paper
• Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.

  2004cited by this paper
• Microenvironmental Interactions and Survival of CLL B-cells

  2004cited by this paper
• Roles of Bim in Apoptosis of Normal and Bcr-Abl-Expressing Hematopoietic Progenitors

  2004cited by this paper
• Activation of the ERK1/2 Signaling Pathway Promotes Phosphorylation and Proteasome-dependent Degradation of the BH3-only Protein, Bim*

  2003cited by this paper
• Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function

  2003cited by this paper
• Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways.

  2003cited by this paper
• Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1.

  2002cited by this paper
• Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors.

  2002cited by this paper
• Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.

  2002cited by this paper
• p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.

  2001cited by this paper
• Molecular cloning and characterization of six novel isoforms of human Bim, a member of the proapoptotic Bcl‐2 family1

  2001cited by this paper
• Molecular cloning and characterization of six novel isoforms of human Bim, a member of the proapoptotic Bcl-2 family.

  2001cited by this paper
• Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–Dependent Expression of Bcl-XL

  2000cited by this paper
• Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.

  2000cited by this paper
• Bryostatin and CD40‐ligand enhance apoptosis resistance and induce expression of cell survival genes in B‐cell chronic lymphocytic leukaemia

  1999cited by this paper
• B-cell chronic lymphocytic leukemia: a bird of a different feather.

  1999cited by this paper
• Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.

  1998cited by this paper
• Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells.

  1998cited by this paper
• Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro

  1996cited by this paper
• p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.

  1994cited by this paper
• Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways

  year unknowncited by this paper

• CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.

  2026cites this paper
• CD86, the double agent: Significance of CD86 expression in B‐cell malignancies

  2025cites this paper
• G-protein coupled receptor kinase-2 regulates the migration of chronic lymphocytic leukaemia cells to sphingosine-1 phosphate in vitro and their trafficking in vivo

  2025cites this paper
• Targeting the tumor microenvironment for treating double refractory chronic lymphocytic leukemia.

  2024cites this paper
• T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells

  2024cites this paper
• Metabolic signature and response to glutamine deprivation are independent of p53 status in B cell malignancies

  2024cites this paper
• A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia

  2023cites this paper
• The Role of the Microenvironment and Cell Adhesion Molecules in Chronic Lymphocytic Leukemia

  2023cites this paper
• In Vitro 3D Spheroid Culture System Displays Sustained T Cell-dependent CLL Proliferation and Survival

  2023cites this paper
• Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation

  2023cites this paper
• In vitro lymph node-mimicking 3D model displays long-term T cell-dependent CLL proliferation and survival

  2023cites this paper
• Ex vivo culture of malignant primary B cells

  2022cites this paper
• In Vitro and In Vivo Models of CLL–T Cell Interactions: Implications for Drug Testing

  2022cites this paper
• JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL

  2022cites this paper
• Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax

  2022cites this paper
• Characterization of metabolic alterations of Chronic Lymphocytic Leukemia in the lymph node microenvironment.

  2022cites this paper
• Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations

  2022cites this paper
• Sensitivity of canine hematological cancers to BH3 mimetics

  2022cites this paper
• Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case

  2022cites this paper
• In vivo, ex vivo and in vitro dasatinib activity in chronic lymphocytic leukemia

  2021cites this paper
• A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia

  2021cites this paper
• Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia

  2021cites this paper
• Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL

  2021cites this paper
• Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer

  2020cites this paper
• Gene Expression Profiling Predicts Sensitivity of Chronic Lymphocytic Leukemia Cells to Dasatinib

  2020cites this paper
• A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell–Mediated Antitumor Responses in Human B-cell Malignancies

  2020cites this paper
• CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells

  2020cites this paper
• Human CXCR5+PD‐1+ CD8 T cells in healthy individuals and patients with hematologic malignancies

  2020cites this paper
• Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.

  2019cites this paper
• Apoptotic resistance in chronic lymphocytic leukemia and therapeutic perspectives

  2019cites this paper
• Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.

  2018cites this paper
• Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition

  2017cites this paper
• 5 MACROPHAGES CONFER SURVIVAL SIGNALS VIA CCR 1-DEPENDENT TRANSLATIONAL MCL-1 INDUCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA

  2017cites this paper
• CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis

  2017cites this paper
• Tumor cell-associated immune checkpoint molecules - Drivers of malignancy and stemness.

  2017cites this paper
• Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia

  2017cites this paper
• 13 Genetics of Chronic Lymphocytic Leukemia : Practical Aspects and Prognostic Significance

  2017cites this paper
• 8 Pathophysiology of Protein Kinase C Isozymes in Chronic Lymphocytic Leukaemia

  2017cites this paper
• Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents

  2016cites this paper
• Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1.

  2016cites this paper
• Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.

  2016cites this paper
• The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells

  2016cites this paper
• Macrophage-mediated chronic lymphocytic leukemia cell survival is independent of APRIL signaling

  2016cites this paper
• Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.

  2016cites this paper
• IL-21 AND IL-4 DISTINCTLY AFFECT NF-ΚB BINDING ON THE BCL-XL PROMOTER IN CLL CELLS

  2016cites this paper
• The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells

  2016cites this paper
• Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling

  2016cites this paper
• The interplay between microenvironmental signaling and novel targeted drugs in CLL

  2016cites this paper
• STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia

  2016cites this paper
• Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma

  2015cites this paper
• Mitochondrial apoptosis: killing cancer using the enemy within

  2015cites this paper
• Broad targeting of resistance to apoptosis in cancer

  2015influential citation
• Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia

  2015cites this paper
• Strategies targeting apoptosis proteins to improve therapy of chronic lymphocytic leukemia.

  2015cites this paper
• Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells.

  2015cites this paper
• Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.

  2014cites this paper
• The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-κB Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells

  2014cites this paper
• Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199

  2014cites this paper
• BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future

  2014cites this paper
• Lyn-mediated procaspase 8 dimerization blocks apoptotic signaling in B-cell chronic lymphocytic leukemia.

  2014cites this paper
• By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells.

  2014cites this paper
• Efficacy and safety of first-line therapy with chlorambucil, rituximab and lenalidomide (Revlimid ® ) (CR 2 ) in elderly patients and young frail patients with advanced Chronic Lymphocytic Leukemia (CLL): a phase I/II trial

  2014cites this paper
• Obinutuzumab (Gazyva®), a Novel Glycoengineered Type II CD20 Antibody for the Treatment of Chronic Lymphocytic Leukemia and Non‐Hodgkin's Lymphoma

  2014cites this paper
• and by a activating compound in chronic lymphocytic leukemia cells

  2014cites this paper
• Cap-Translation Inhibitor, 4EGI-1, Restores Sensitivity to ABT-737 Apoptosis through Cap-Dependent and -Independent Mechanisms in Chronic Lymphocytic Leukemia

  2013cites this paper
• Mimicking the microenvironment in chronic lymphocytic leukaemia – where does the journey go?

  2013cites this paper
• Biology of Chronic Lymphocytic Leukemia in Different

  2013cites this paper
• Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.

  2013influential citation
• Cancer Therapy : Preclinical In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors

  2013cites this paper
• CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex

  2013cites this paper
• CD137 Is Induced by the CD40 Signal on Chronic Lymphocytic Leukemia B Cells and Transduces the Survival Signal via NF-κB Activation

  2013cites this paper
• Novel Bruton’s tyrosine kinase inhibitors currently in development

  2013cites this paper
• IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells.

  2013cites this paper
• A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization.

  2013cites this paper
• The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia.

  2013cites this paper
• Hematological malignancies: disease pathophysiology of leukemic stem cells.

  2013cites this paper
• Role of stromal cell-mediated Notch signaling in CLL resistance to chemotherapy

  2012cites this paper
• Dasatinib Inhibits CXCR4 Signaling in Chronic Lymphocytic Leukaemia Cells and Impairs Migration Towards CXCL12

  2012cites this paper
• Dasatinib Inhibits CXCR 4 Signaling in Chronic Lymphocytic Leukaemia Cells and Impairs Migration Towards CXCL 12

  2012influential citation
• Evaluation of LMP-420: A Novel, Nontoxic Drug with Anti-Inflammatory Properties and Therapeutic Potential for CLL

  2012cites this paper
• Cancer Therapy : Preclinical Le fl unomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells

  2012cites this paper
• The microenvironment and treatment resistance in chronic lymphocytic leukemia

  2012cites this paper
• Genetics of Chronic Lymphocytic Leukemia: Practical Aspects and Prognostic Significance

  2012cites this paper
• Cancer Therapy : Preclinical Tipping the Noxa / Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia

  2012cites this paper
• Pathophysiology of Protein Kinase C Isozymes in Chronic Lymphocytic Leukaemia

  2012cites this paper
• Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches

  2012cites this paper
• Primary CLL cells are resistant to cellular inhibitor apoptosis protein ( cIAP ) antagonists

  2012cites this paper
• In Vitro Sensitivity Testing in the Assessment of Anti-CLL Drug Candidates

  2012cites this paper
• CD40 stimulation induces vincristine resistance via AKT activation and MRP1 expression in a human multiple myeloma cell line.

  2012cites this paper
• Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL

  2012cites this paper
• In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors

  2012influential citation
• Chronic lymphocytic leukemia specific T-cell subset alterations are clone-size dependent and not present in monoclonal B lymphocytosis

  2012cites this paper
• Dichotomy in NF-κ B signaling and chemoresistance in IGHV mutated versus unmutated CLL cells upon CD 40 / TLR 9 triggering

  2012cites this paper
• Leflunomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells

  2011cites this paper
• Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro‐survival microenvironmental signals

  2011cites this paper
• The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms

  2011cites this paper
• Mechanisms of Action of a Dual Cdc7/Cdk9 Kinase Inhibitor against Quiescent and Proliferating CLL Cells

  2011cites this paper
• Cytogenetic methods in chronic lymphocytic leukemia.

  2011cites this paper
• CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101.

  2011cites this paper
• Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies

  2011cites this paper